NCT06268210View on ClinicalTrials.gov

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Lazertinib+Pemetrexed+Carboplatin

Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)

DRUG

Lazertinib

Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.

Trial Locations (1)

Unknown

Severance hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT06268210 - Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter